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Abstract
Background: The interleukin-1 (IL-1) family of cytokines is involved in the inflammatory and repair reactions of
skeletal muscle during and after exercise. Specifically, plasma levels of the IL-1 receptor antagonist (IL-1ra) increase
dramatically after intense exercise, and accumulating evidence points to an effect of genetic polymorphisms on
athletic phenotypes. Therefore, the IL-1 family cytokine genes are plausible candidate genes for athleticism. We
explored whether IL-1 polymorphisms are associated with athlete status in European subjects.
Methods: Genomic DNA was obtained from 205 (53 professional and 152 competitive non-professional) Italian
athletes and 458 non-athlete controls. Two diallelic polymorphisms in the IL-1b gene (IL-1B) at -511 and +3954
positions, and a variable number tandem repeats (VNTR) in intron 2 of the IL-1ra gene (IL-1RN) were assessed.
Results: We found a 2-fold higher frequency of the IL-1RN 1/2 genotype in athletes compared to non-athlete
controls (OR = 1.93, 95% CI = 1.37-2.74, 41.0% vs. 26.4%), and a lower frequency of the 1/1 genotype (OR = 0.55,
95% CI = 0.40-0.77, 43.9% vs. 58.5%). Frequency of the IL-1RN 2/2 genotype did not differ between groups. No
significant differences between athletes and controls were found for either -511 or +3954 IL-1B polymorphisms.
However, the haplotype (-511)C-(+3954)T-(VNTR)2 was 3-fold more frequent in athletes than in non-athletes (OR =
3.02, 95% CI = 1.16-7.87). Interestingly, the IL-1RN 1/2 genotype was more frequent in professional than in non-
professional athletes (OR = 1.92, 95% CI = 1.02-3.61, 52.8% vs. 36.8%).
Conclusions: Our study found that variants at the IL-1ra gene associate with athletic status. This confirms the
crucial role that cytokine IL-1ra plays in human physical exercise. The VNTR IL-1RN polymorphism may have
implications for muscle health, performance, and/or recovery capacities. Further studies are needed to assess these
specific issues. As VNTR IL-1RN polymorphism is implicated in several disease conditions, athlete status may
constitute a confounding variable that will need to be accounted for when examining associations of this
polymorphism with disease risk.
Background
Factors that affect athletic performance are only partially
defined. However, there are accumulating data indicat-
ing that both pro- and anti-inflammatory responses can
play a role. Prolonged strenuous exercise results in an
activation of the acute phase response with some simila-
rities to sepsis [1]. The induction of a systemic cytokine
response, including elevated plasma levels of interleukin
(IL)-1 receptor antagonist (IL-1ra), IL-6, IL-8, IL-10, and
granulocyte colony-stimulating factor (G-CSF), following
intense physical activity, is well documented [1-5]. IL-
1ra is a member of the IL-1 family, which includes the
classical IL-1 (a and b) cytokines, IL-18 and the newly
described IL-1F 5-11 [6]. IL-1ra acts as an antagonist of
the IL-1 receptor type I (IL-1RI) and prevents IL-1 (a
and b)-dependent signaling. In the absence of IL-1ra,
the activity of IL-1 is unopposed, promoting rampant
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inflammation. Recent research has shown that deficiency
of IL-1ra in humans can cause IL-1-mediated systemic
and local inflammation that affect infants soon after
birth [7]. IL-1a is an IL-1RI agonist with proinflamma-
tory action, that acts primarily as an intracellular tran-
scriptional regulator; it is not found in high
concentration in the circulation. In contrast, IL-1b can
be secreted from cells in large quantities and thus it is
commonly found in serum and secretions. In general,
IL-1b acts synergistically with tumor necrosis factor
(TNF)-a, activating proinflammatory responses in a
wide range of cells and promoting the acute phase
response [6]. For these reasons IL-1b levels have been
studied in relation to physical activity. However, the cir-
culating concentration of IL-1b is either unaffected by
exercise, or it exhibits relatively small, delayed changes
[1,2]. In contrast to minimal changes in serum circulat-
ing IL-1b after exercise, there is evidence of increased
local IL-1b levels after exercise within skeletal muscle;
this is most likely associated with response to micro-
injury of skeletal muscle caused by intense physical
activity [8]. Interestingly, Mahoney and colleagues [9]
demonstrated that elevated gene expression of IL-1RI is
induced in skeletal muscle after eccentric exercise.
Inflammatory and chemoattractant mediators likely pro-
mote phagocytosis of trauma-induced cellular debris by
macrophages and these cells can continue to secrete IL-
1b up to 5 days post-injury [8]. It is of note that accu-
mulation and activation of muscle resident macrophages
is a rich source of growth factors postulated to stimulate
myogenesis [4]. Thus, inflammation may serve as a
mechanism promoting hypertrophy. However, pre- and
post-exercise levels of inflammatory factors display con-
siderable variation among people, and this is likely influ-
enced, at least partially, by genetic variation [10,11].
IL-1b plays an important role in the regulation of
acute inflammatory response [12]. After an insult to the
body, IL-1b is one of the first pro-inflammatory cyto-
kines to be activated. Intense physical activity can cause
micro-injury to skeletal muscle, and cytokines such as
IL-1b and TNF-a are thought to initiate and regulate
the repair process. IL-1b is able to induce the secretion
of several inflammatory factors, such as IL-6, IL-8, TNF-
a, and GM-CSF, by many different cell types including
myoblasts, smooth and skeletal muscle cells, fibroblasts,
macrophages, peripheral blood mononuclear cells
(PBMC) and endothelial cells [12-14]. IL-1b binds IL-
1RI on the surface of a variety of cells and initiates a
cascade of events leading to recruitment and activation
of macrophages and neutrophils. However, inflammation
must be strictly regulated to avoid secondary tissue
damage and myopathy. The activity of IL-1b is modu-
lated mainly by a receptor antagonist (IL-1ra) that inhi-
bits IL-1 action by competing for its receptor [6,15]. In
healthy individuals, IL-1ra is easily detectable in plasma
(concentrations are hundreds of pg/mL), but IL-1b
levels are usually undetectable (very few or less than pg/
mL) [15,16]. In general, after an insult to the body both
IL-1b and IL-1ra increase, and thus, plasma levels of
these cytokines are positively correlated [17]. However,
the final inflammatory activity of IL-1b is considered to
be dependent on the actual ratio of IL-1b over IL-1ra
[7,18].
There is evidence that susceptibility to inflammation
is influenced by genetic variation in cytokine genes
[14,19]. Several studies showed that polymorphisms in
the IL-1b (IL-1B) and IL-1ra (IL-1RN) genes correlate
with altered protein expression in vitro [14,20] and in
vivo [10,16,21,22]. These two genes map close to each
other on human chromosome 2 [12]. Polymorphisms
in the IL-1 gene cluster associate with many clinical
conditions, including inflammatory and infectious dis-
eases (periodontal and arterial diseases, altered meta-
bolic conditions, type 2 diabetes, type 2 diabetes
complications, gastric cancer, rheumatoid arthritis,
ankylosing spondylitis, systemic inflammation, myopa-
thies, Alzheimer’s disease, malaria, and bacterial vagi-
nosis) [6,12,17,19,21,23-31]. Mostly, two single
nucleotide polymorphisms (SNPs) in IL-1B have been
studied for disease predisposition, one at position -511
in the promoter region [32] and another at position
+3954 in exon 5 (TaqI restriction site polymorphism)
[18]. In addition, a pentaallelic polymorphic site in
intron 2 of the IL-1RN gene consisting in a variable
number tandem repeats (VNTR, 86 bp repeats) has
been extensively investigated in relation to a variety of
pathological conditions, including inflammatory myo-
pathies [6,18,19,29,33,34].
Recently, a study performed on 24 sedentary subjects
(of unspecified ethnicity) selected on the basis of their
haplotype pattern in the IL-1 gene cluster (based on
specific combinations of +4845 IL-1A, +3954 IL-1B,
-511 IL-1B, and -3737 IL-1B polymorphisms) showed
that subjects C/C for IL-1B +3954 who carry allele 2 at
IL-1RN +2018 were associated with the inflammation of
skeletal muscle, following acute resistance exercise [10].
The aim of this study was to investigate whether poly-
morphisms in the IL-1b and IL-1ra genes affect athletic
status, competitive athlete vs. non-athlete. We evaluated
whether the genotype frequencies of -511 and +3954
SNPs of IL-1B, and intron 2 VNTR of IL-1RN vary
between athletes and non-athletes. Athletes of National
or Regional competitive standard were recruited. This
analysis was performed in a relatively homogeneous eth-
nic group of Caucasian Italian subjects because associa-
tions between polymorphisms in immune system-related
genes may be confounded by allele frequency differences
between ethnic groups [35,36]. We examined whether
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the polymorphisms of these genes are associated with
being a professional (high-grade) or non-professional
(medium-grade) athlete.
methods
Subjects and biological samples
The study population consisted of subjects attending the
Galeazzi Hospital for routine blood testing. Exclusion
criteria were age younger than 18 years and presence of
a pathologic condition or chronic major diseases such as
diabetes, autoimmune diseases, cardiovascular diseases
and malignancies. Athletes were enrolled from teams of
Italian professional or non-professional athletes during
routine physical examinations. Controls were recruited
from the general Italian population of unrelated subjects
after the following questions: 1) are you or have you
ever been a trained athlete?; 2) did you ever participate
in an official athletic competition? All control subjects
were without any competitive sport experience, they
declared they had never been an athlete or participated
in any athletic competition or athletic training. All sub-
jects were Caucasian. The study was approved by the
Institutional Review Board of Milan Azienda Sanitaria
Locale (ASL). The methods used in this study were in
accordance with the Helsinki Declaration of 1975 as
revised in 1996. All eligible participants were enrolled
consecutively after written informed consent.
Out of 688 subjects enrolled, 25 subjects were
excluded from the study because 14 did not fulfill inclu-
sion criteria and 11 had non-interpretable laboratory
data. The final analyses were performed on 663 subjects,
including 205 (30.9%) athletes and 458 (69.1%) non-ath-
lete controls. The study population of 205 athletes
included 53 high-grade professionals (50 current and 3
who had been professional athletes) who compete(d) at
National level and 152 medium-grade non-professional
athletes who participate in Regional athletic competi-
tions. Specifically, high-grade athletes group included
National Italian team grade (some of these athletes par-
ticipated in Olympic Games, and some were medallists
in International Games) or Third Division soccer
players. The “caliber” of an Italian Third Division soccer
team is similar to National teams of several European
countries. The non-professional athlete group included
athletes who are highly involved in sports activities
(training and competitions >10 h/week).
Among the athletes there were 139 females and 66
males. Age range of study athletes was 18-53 years. A
total of 458 healthy Italian non-athlete subjects of both
sexes in the age range of 18-53 years (mean 33.6 ± 9.23
years) constituted the control group.
Blood samples were obtained from seated and fasting
subjects in the morning from the antecubital vein with
evacuated ethylenediamine tetra acetic acid (EDTA) tubes
(Vacutainer Tubes, Becton-Dickinson, Franklin Lakes, NJ,
USA). Samples were centrifuged at 2000 g for 10 min at
4°C and the cellular pellet was processed for DNA extrac-
tion. Personnel isolating and processing the DNA were
blinded to the subjects’ demographic characteristics.
IL-1B and IL-1RN polymorphisms gene identification
Genomic DNA was extracted from the blood pellet frac-
tion according to the standard proteinase-K digestion
and ethanol extraction method. The extracted DNA was
then stored at -20°C until further analysis.
To examine the -511 SNP (rs16944) [37], the promoter
region of IL-1B was amplified by PCR, using the primers
5’-TGGCATTGATCTGGTTCATC-3’ and 5’-GTTTAG-
GAATCTTCCCACTT-3’ as described [32]. The protocol
included 35 cycles at 94°C for 1 min, 55°C for 30 s, and
72°C for 30 s, and a final extension at 72°C of 5 min. At
the end of the procedure the amplicons were digested
with AvaI at 37°C for 3 hours. Fragments were analyzed
after electrophoresis on 10% acrylamide gels and visua-
lized with ethidium bromide. This gave products of 190
bp and 114 bp (C allele) or 304 bp (T allele) [31]. Out of
663 study subjects, 4 data were not available for the -511
genotype.
To determine the +3954 (rs1143634) [37] SNP geno-
type, the polymorphic region containing the TaqI
restriction site (designed as +3953 in older literature
[30]) was amplified using the following primers: 5’-
GTTGTCATCAGACTTTGACC-3’ and 5’-TTCAGTT-
CATATGGACCAGA-3’ [18]. The 249 bp products were
digested with TaqI at 65°C for 1 hour, resulting in frag-
ments that either remained intact (T allele) or were
digested into 2 fragments of 135 and 114 bp (C allele).
The restriction fragments were analyzed by electrophor-
esis on 10% acrylamide gels and visualized with ethi-
dium bromide [31].
The IL-1RN intron 2 VNTR polymorphism (rs380092)
[38] was analyzed using 5’-CTCAGCAACACTCCTAT-
3’ and 5’-TCCTGGTCTGCAGGTAA-3’ as primers
[18,33]. The PCR products of 410 bp (allele 1 = 4
repeats of the 86 bp region), 240 bp (allele 2 = 2
repeats), 500 bp (allele 3 = 5 repeats), 325 bp (allele 4 =
3 repeats), 595 bp (allele 5 = 6 repeats) [18] were ana-
lyzed by electrophoresis on 8% acrylamide gel stained
with ethidium bromide [31]. A blinded quality control
was performed in a random subset of 20 samples, which
were sequenced by use of ABI Prism 310 genetic analy-
zer (Applied Biosystems). The sample consisted of 11
subjects 1/1, 6 subjects 1/2, and 3 subjects 2/2 genotype;
a 100% correspondence with gel data was obtained.
Statistical analysis
The genotype frequencies for each polymorphism were
compared by 2-sided Pearson chi-square or Fisher’s
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exact test as appropriate, using STATA statistical soft-
ware version 10, College Station, TX, USA and Power-
marker [39]. The odds ratio (OR) and the 95%
confidence interval (CI) were calculated to evaluate the
genotype effects of each genotype against all others.
Tests for deviations from Hardy-Weinberg equilibrium
(HWE) were performed in Powermarker, using a chi-
square distribution in cases and controls separately for
each SNP. Haplotype analysis was performed with the
program Unphased [40]. Haplotypes estimated to be
below 1% in frequency were not reported. Due to the
low allele frequencies of the 3, 4 and 5 allele of IL-
1RN, the intron 2 VNTR genotypes were grouped into
the short allele (S, allele 2) and the long alleles (L,
alleles 1, 3, 4, and 5) according to Machado et al. [41].
Linkage disequilibrium (LD) between the two SNPs in
IL-1B and the VNTR short and long alleles in IL-1RN
was determined using Haploview [42]. Differences in
the haplotype distributions between cases and controls
were determined by likelihood ratio tests. The refer-
ence distribution for which all the other haplotypes
were compared against was the most common haplo-
type. The OR was considered significant if the CI did
not cross unity. The P-value for each haplotype was
determined by comparing the haplotype against all
others. Therefore, a P-value may be slightly significant
even if the OR is not.
Results
The study population consisted of 205 athletes; of these
53 were professional (high-grade, National level) and
152 were non-professional (medium-grade, Regional
level, recreational athletes not paid for performing com-
petitions) athletes regularly participating in athletic com-
petitions. Controls were 458 healthy non-athletes.
Demographic characteristics and sport disciplines prac-
ticed by the 205 athletes are shown in Table 1.
A total of 663 study subjects were genotyped for the
three gene loci (IL-1B in position -511 and +3954; and
IL-1RN intron 2 VNTR).
Neither case nor control samples deviated from Hardy
Weinberg equilibrium (HWE) at site -511 or site +3954.
The controls deviated from HWE at the VNTR in IL-
1RN (P = 0.001); while athletes marginally deviated from
HWE (P = 0.097). Athletes and controls did not differ in
the distribution of -511 IL-1B genotypes; 38.8% athletes
vs. 44.8% controls were homozygous CC, 48.8% athletes
vs. 45.9% controls were heterozygous CT, and 12.4%
athletes vs. 9.4% controls were homozygous TT (Table
2). The two groups also did not differ significantly in
allele frequency (P = 0.11).
Genotype and allele distribution of IL-1B +3954 gene
polymorphism are shown in Table 3. Athletes and con-
trols did not differ; 60.0% athletes vs. 62.2% controls
were homozygous CC, 36.1% athletes vs. 32.3% controls
were heterozygous CT, and 3.9% athletes vs. 5.5% con-
trols were homozygous TT. The two groups also did
not differ significantly in allele frequency (P = 0.89).
For the IL-1RN VNTR polymorphism three alleles
(allele 1, 2 and 3) were common in our study; allele 4
was found in 3 subjects (one genotype 1/4 and two gen-
otypes 2/4, all in the control group) and allele 5 was
detected in only 1 subject (one genotype 1/5, in the ath-
lete group). The most common allele, the IL-1RN*1
allele, was less frequent in athletes than in controls
(65.4% vs. 74.0%, P = 0.001), whereas the second com-
monest allele, IL-1RN*2, had an allele frequency higher
in athletes than controls (32.2% vs. 22.9%, P < 0.001),
finally, IL-1RN*3 had similar frequency in athletes and
controls (P = 0.57) (overall alleles, P = 0.001) (Table 4).
Specifically, athletes were less likely to have the 1/1 gen-
otype (OR = 0.55, 95% CI 0.40-0.77), and 2-fold more
likely to be 1/2 (OR = 1.93, 95% CI 1.37-2.74). Athletes
and controls did not differ in frequency of the 2/2 geno-
type. However, we observed increased frequencies of
cumulative 1/2, 2/2, 2/3 and 2/4 genotypes in athletes
(53.7%) compared with controls (36.7%), OR = 2.00
(95% CI = 1.43-2.79), suggesting a dominant effect of
the 2 allele. These observations were significant in both
male and female athletes when analyzed separately (data
not shown, see additional File 1). Genotypes that
included the 3 allele did not differ between athletes and
controls.
Table 1 Demographic characteristics and sport activities
of 205 study athletes
Characteristics n = 205
Age (years), mean ± SD 25.5 ± 6.68
Body mass index (kg/m2), mean ± SD 22.3 ± 3.20
High-grade professional athletes, n (%) 53 (25.9)
Females, n (%) 139 (67.8)a
Males, n (%) 66 (32.2)b
Volleyball, n (%) 82 (40.0)
Soccer, n (%) 34 (16.6)c
Rugby, n (%) 26 (12.7)d
Triathlon, n (%) 21 (10.2)e
Basketball, n (%) 8 (3.9)
Martial arts, n (%) 6 (2.9)
Track-and field sports, n (%) 6 (2.9)
Running, n (%) 3 (1.5)
Handball, n (%) 3 (1.5)
Swimming, n (%) 3 (1.5)
Others, n (%) 13 (6.3)
a4 were professional athletes
b48 were professional athletes
c22 were professional athletes
d23 were professional athletes
e8 were professional athletes
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In a secondary analysis (Table 5), we compared IL-1RN
genotypes between the 53 professional athletes and the
152 non-professional athletes. Interestingly, we found that
the 1/2 VNTR genotype was almost 2-fold more frequent
in professional than in non-professional athletes (OR =
1.92, 95% CI = 1.02-3.61). No other significant differences
were noted between professional and recreational athletes.
Comparison of professional athletes with non-athletes
revealed that genotype 1/2 VNTR was 3-fold more
frequent in high-grade athletes (OR = 3.12, 95% CI =
1.75-5.56) (Table 5). The same genotype was only
1.6-fold more frequent in medium grade/recreational
athletes than in non-athletes (OR = 1.62, 95% CI =
1.10-2.40) (Table 5). The 1/1 genotype was 2.5-fold
more frequent in non-athletes than in professional ath-
letes (OR = 2.52, 95% CI = 1.40-4.56), but 1.6-fold more
frequent in non-athletes than in recreational athletes
(OR = 1.61, 95% CI = 1.11-2.33). Overall (frequencies
Table 2 Genotype frequencies of IL-1B promoter at position -511 in 659 white subjects, comparison of 201 athletes
and 458 non-athlete controls
All subjects
(n = 659)
Athletes
(n = 201)
Controls
(n = 458)
Odds ratio
(95% CI)
P-value
Athletes versus controls
IL-1B promoter genotype (-511) 0.264
CC 283 (43.0%) 78 (38.8%) 205 (44.8%) 0.78 (0.56-1.10) 0.155
CT 308 (46.7%) 98 (48.8%) 210 (45.9%) 1.12 (0.81-1.57) 0.491
TT 68 (10.3%) 25 (12.4%) 43 (9.4%) 1.37 (0.81-2.31) 0.236
IL-1B promoter allele 0.111
Allele C 874 (66.3%) 254 (63.2%) 620 (67.7%)
Allele T 444 (33.7%) 148 (36.8%) 296 (32.3%)
Table 3 Genotype frequencies of IL-1B exon 5 at position +3954 in 663 subjects, comparison of 205 athletes and 458
non-athlete controls
All subjects
(n = 663)
Athletes
(n = 205)
Controls
(n = 458)
OR
(95% CI)
P-value
Athletes versus controls
IL-1B exon 5 genotype (+3954) 0.495
CC 408 (61.5%) 123 (60.0%) 285 (62.2%) 0.91 (0.65-1.28) 0.586
CT 222 (33.5%) 74 (36.1%) 148 (32.3%) 1.18 (0.84-1.67) 0.340
TT 33 (5.0%) 8 (3.9%) 25 (5.5%) 0.70 (0.31-1.59) 0.395
IL-1B exon 5 allele 0.891
Allele C 1038 (78.3%) 320 (78.0%) 718 (78.4%)
Allele T 288 (21.7%) 90 (22.0%) 198 (21.6%)
Table 4 Genotype frequencies of IL-1RN VNTR, comparison of 205 athletes and 458 non-athlete controls
All subjects
(n = 663)
Athletes
(n = 205)
Controls
(n = 458)
OR
(95% CI)
P-value
Athletes versus controls
IL-1RN VNTR genotype < 0.001
1/1 358 (54.0%) 90 (43.9%) 268 (58.5%) 0.55 (0.40-0.77) < 0.001
1/2 205 (30.9%) 84 (41.0%) 121 (26.4%) 1.93 (1.37-2.74) < 0.001
1/3 23 (3.5%) 3 (1.5%) 20 (4.4%) 0.33 (0.10-1.11) 0.067
2/2 64 (9.7%) 22 (10.7%) 42 (9.2%) 1.19 (0.69-2.05) 0.529
2/3 7 (1.1%) 4 (2.0%) 3 (0.7%) 3.02 (0.67-13.6) 0.211
1/2 and 2/2 and 2/3 and 2/4 278 (41.9%) 110 (53.7%) 168 (36.7%) 2.00 (1.43-2.79) < 0.001
1/3 and 2/3 and 3/3 32 (4.8%) 8 (3.9%) 24 (5.2%) 0.73 (0.32-1.66) 0.458
IL-1RN VNTR allele 0.001
Allele 1 946 (71.3%) 268 (65.4%) 678 (74.0%) 0.66 (0.52-0.85) 0.001
Allele 2 342 (25.8%) 132 (32.2%) 210 (22.9%) 1.60 (1.23-2.07) < 0.001
Allele 3 34 (2.6%) 9 (2.2%) 25 (2.7%) 0.80 (0.37-1.73) 0.570
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already reported in Table 4), the 1/1 genotype was 1.8-
fold more frequent in non-athletes than in all athletes
(OR = 1.80, 95% CI = 1.29-2.51).
Haplotype analyses were performed, using all three
polymorphisms (Table 6). There was virtually no LD
between any of the three sites in athletes (Figure 1) or
non-athletes (r2 ≤ 0.05) (Figure 2). The three site hap-
lotype was differentially distributed between athletes
and controls (P = 0.012). Individually only one haplo-
type associated with athlete status. Specifically, (-511)
C-(+3954)T-(VNTR)2 was 3 times more common in
athletes than non-athletes (OR = 3.02, 95%CI = 1.15-
7.87). We also analyzed the three pair wise haplotypes
and found that only those that included the VNTR
were significant, indicating that the association was
related to the VNTR or a marker in linkage disequili-
brium with it.
Discussion
Polymorphisms and exercise
Our finding that athletes have significantly different gen-
otypes than non-athletes reinforces the evidence that
athletic performance is associated with genetic constitu-
tion in addition to environmental/behavioral factors.
However, we want to emphasize that carriage of a speci-
fic genetic polymorphism is only a predisposing factor
and does not by itself necessarily result in elite perfor-
mance. Clearly, more than one biologic process is neces-
sary for the development of high-grade athletic
performance.
In general, genetic associations of athletic phenotype
are only partially understood. Increased knowledge in
this research may help to identify physiological and bio-
chemical pathways related to exercise [43]. Genetic stu-
dies so far focused on candidate genes (over 200) mainly
involved in cardiovascular performance, including angio-
tensin-converting enzyme (ACE) and proteins involved
in skeletal-muscle activity such as a-actinins [44-46].
Immunity-related genes have been minimally explored
[45]. A study that examined polymorphisms of the IL-15
receptor-a (IL-15RA) gene identified a SNP strongly
associated with muscle hypertrophy in young subjects
(76 men and 77 women) of mixed ethnicity who per-
formed resistance exercise training [47]. Two studies
performed in non-athletes reported that the -174G/C
variant in the IL-6 gene affected the response to exercise
by modulating changes in serum concentrations of IL-6
[48] and high-density lipoprotein cholesterol (HDL-C)
[49]. However, Walston and colleagues [50] identified
no significant relationship between IL-6 SNPs or IL-6
haplotypes and serum IL-6 concentration, grip, knee, or
hip strength, or frailty in 463 older women.
Table 5 Genotype frequencies of IL-1RN VNTR comparison of 53 professional athletes and 152 non-professional
athletes and 458 non-athlete controls
Professional
Athletes
(n = 53)
Non-professional
Athletes
(n = 152)
ORa
(95% CI)
P-valuea ORb
(95% CI)
P-valueb ORc
(95% CI)
P-valuec
IL-1RN VNTR genotype 0.084 < 0.001 0.047
1/1 19 (35.8%) 71 (46.7%) 0.64 (0.33-
1.22)
0.200 0.40 (0.22-
0.72)
0.002 0.62 (0.43-
0.90)
0.012
1/2 28 (52.8%) 56 (36.8%) 1.92 (1.02-
3.61)
0.042 3.12 (1.75-
5.56)
< 0.001 1.62 (1.10-
2.40)
0.014
1/3 0 3 (2.0%) 0.98 (0.96-
1.00)
0.570 0.96 (0.94-
0.98)
0.250 0.44 (0.13-
1.51)
0.225
2/2 3 (5.7%) 19 (12.5%) 0.42 (0.12-
1.48)
0.205 0.59 (0.18-
1.99)
0.607 1.41 (0.80-
2.52)
0.236
2/3 2 (3.8%) 2 (1.3%) 2.94 (0.40-
21.4)
0.275 5.95 (0.97-
36.4)
0.086 2.02 (0.33-
12.2)
0.603
1/2 and 2/2 and 2/3
and 2/4
33 (62.3%) 77 (50.7%) 1.61 (0.85-
3.05)
0.145 2.84 (1.58-
5.12)
< 0.001 1.77 (1.22-
2.57)
0.002
1/3 and 2/3 and 3/3 2 (5.2%) 6 (3.7%) 0.95 (0.19-
4.88)
1.000 0.71 (0.16-
3.09)
1.000 0.74 (0.30-
1.85)
0.523
IL-1RN VNTR allele 0.498 0.019 0.023
Allele 1 67 (63.2%) 201(66.1%)
Allele 2 36 (34.0%) 96 (31.6%)
Allele 3 2 (1.9%) 7 (2.3%)
aComparison between professional and non-professional athletes
bComparison between professional athletes and non-athlete controls
cComparison between non-professional athletes and non-athlete controls
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IL-1b and IL-1ra roles in human disease and exercise
The inflammatory response after intensive exercise is a
well documented phenomenon; the coordinated action
of cytokines is considered crucial for regulation of
inflammatory reactions responsible for immune defenses
and muscle repair. Conceivably, a delay in the removal
of dead cells increases the likelihood of a slow recovery.
IL-1b is a crucial proinflammatory cytokine involved
in initiating and amplifying the inflammatory response;
it stimulates the production of prostaglandins and nitric
oxide, both of which are highly inflammatory, and it
induces the synthesis of several chemokines [6,12]. IL-
1b is a highly active pleiotropic cytokine with several
known functions. It has many systemic effects in the
protection of the body, including response to stress and
the metabolism of insulin, lipids and bone [12]. Injecting
a few nanograms per kilogram of IL-1b results in an
increase of acute phase proteins, plasma IL-6, neutro-
philia and thrombocytosis [12]. Recent evidence suggests
that IL-1b plays a key pathogenic role in many human
conditions, including cardiovascular diseases [23,51],
and in the central nervous system effects of exercise
[52,53]. The bioactivity of IL-1b is finely modulated as it
is a potentially harmful factor able to promote tissue
damage and fever. The main cytokine that counteracts
the effects of IL-1b is IL-1ra, a naturally occurring inhi-
bitor of IL-1b that binds to IL-1 receptor type I, but
does not elicit post-receptor signaling [7]. In addition,
IL-1ra seems to modulate the IL-1 decoy receptor, IL-1
receptor type II [54]. IL-1ra protein is produced by
many cells that can synthesize IL-1b, mainly by hepato-
cytes, adipocytes, neutrophils and macrophages. The IL-
1ra plasma levels are co-coordinately regulated by both
the IL-1RN and IL-1B genes [16,22]. The biological
functions of IL-1ra are not completely understood.
Interestingly, at present a recombinant IL-1ra (anakinra)
is approved for use in humans as an anti-inflammatory
therapy in several conditions, such as rheumatic
Table 6 Haplotype frequencies in athletes and non-athlete controls
Athletes
(n = 205)
Controls
(n = 458)
OR (95% CI) P-value
Haplotype (3 sites)
-511, +3954, IL-1RN)a
Haplotype Frequency Haplotype Frequency 0.012
C-C-L 0.360 0.406 1.0 (reference) 0.029
C-C-S 0.117 0.093 1.420 (0.862-2.339) 0.095
C-T-L 0.106 0.160 0.745 (0.436-1.274) 0.051
C-T-S 0.049 0.018 3.016 (1.156-7.867) 0.011
T-C-L 0.171 0.178 1.082 (0.711-1.648) 0.838
T-C-S 0.133 0.107 1.400 (0.891-2.200) 0.054
T-T-L 0.042 0.027 1.762 (0.692-4.487) 0.484
T-T-S 0.022 0.011 2.226 (0.492-10.080) 0.043
Haplotype (2 sites)
-511, +3954 0.264
C-C 0.478 0.498 1.0 (reference) 0.278
C-T 0.154 0.179 0.896 (0.608-1.321) 0.520
T-C 0.303 0.286 1.105 (0.815-1.498) 0.258
T-T 0.065 0.038 1.809 (0.889-3.679) 0.103
+3954, IL-1RN 0.001
C-L 0.529 0.584 1.0 (reference) 0.023
C-S 0.251 0.200 1.386 (1.013-1.897) 0.012
T-L 0.149 0.187 0.879 (0.597-1.292 0.183
T-S 0.071 0.029 2.658 (1.345-5.254) 0.003
-511, IL-1RN 0.003
C-L 0.465 0.566 1.0 (reference) 0.001
C-S 0.166 0.111 1.821 (1.213-2.732) 0.014
T-L 0.214 0.205 1.267 (0.894-1.795) 0.954
T-S 0.155 0.118 1.589 (1.099-2.298) 0.025
aDue to the low allele frequencies of the 3, 4 and 5 alleles of the intron 2 VNTR IL-1RN genotypes were grouped into the short allele (S, allele 2) and the long
alleles (L, alleles 1, 3, 4, and 5).
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diseases, ankilosing spondylitis, chronic Achilles tendi-
nopathy, type 2 diabetes mellitus and systemic inflam-
matory diseases [6,7,51,55].
Several studies found that serum IL-1b concentration
does not change after physical exercise, whereas IL-1ra
concentration significantly increases [1,5]. In this
respect, the profile of systemic cytokines’ changes in
response to exercise differs from that observed in sep-
sis, where there is a relevant increase in both serum
IL-1b and IL-1ra [1]. The rise of circulating anti-
inflammatory cytokines induced by exercise has been
suggested as one of the pathways involved in protec-
tion against several diseases, primarily against cardio-
vascular disease and type 2 diabetes mellitus exerted
by regular exercise [1].
VNTR polymorphism in the intron 2 of the IL-1RN gene
We demonstrated that the genotype -511 in the promo-
ter region and +3954 in exon 5 of IL-1B gene have no
influence on the athletic phenotype. These findings
seem to fit with the in vivo observation that neither
circulating IL-1b, nor IL-1b mRNA levels are signifi-
cantly changed by physical activity [1,9,56].
In contrast, we showed that a specific genotype (1/2)
of the IL-1ra gene, a VNTR in intron 2 of IL-1RN, is
almost 2-fold more frequent in athletes than in non-ath-
letes. Additionally, we observed a dose-effect relation-
ship with the 1/2 IL-1RN genotype being 2-fold more
frequent in professional than in recreational athletes and
3-fold more frequent in professional athletes than in
non-athletes. Thus, our study suggests the 1/2 IL-1RN
frequency is increasing in parallel with the level of ath-
letic grade. We did not observe gender effects.
The precise molecular effects of the IL-1RN poly-
mophisms are not totally clear [22,27]. Possibly, the 1/2
IL-1RN genotype could favor muscle repair and hyper-
trophy in athletes; however, further studies are needed
to clarify this issue [4,47]. This can occur through an
influence on circulating or local levels of IL-1ra in
humans [22,27]. Consistent with this is that the IL-
1RN*2 allele is associated with a higher production of
inflammatory reactions, and therefore, an overall
Figure 1 Linkage disequilibrium plots (r2) are shown for
athletes.
Figure 2 Linkage disequilibrium plots (r2) are shown for non-
athletes.
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increase of IL-1 activity, meaning less effective IL-1ra
inhibitory activity [19,27]. However, contrasting findings
were obtained for the association of IL-1RN*2 with IL-
1ra levels; some authors found that the IL-1RN*2 allele
is associated with reduced IL-1ra [14,57,58], but other
authors observed no association [29] or even increased
IL-1ra [16,18,21]. Some of these discrepancies can be
due to different experimental designs and/or by the pre-
sence of heterogeneity with other polymorphisms in the
IL-1RN gene [27].
In our study athletes were not more likely to be homo-
zygous for the allele 2, a genotype that has been associated
with several pathological conditions of inflammatory or
autoimmune nature [18,19,26,28,34,59,60]. It is of note
that the IL-1RN 2/2 genotype was more likely associated
with disease than the IL-1RN 1/2, especially for gastric
cancer development [19,34,41]. Based on the in vitro
observation that VNTR allele 2 has been associated with a
decreased production of IL-1ra [14,58]; and increased pro-
duction of IL-1b [20] in a dose-dependent fashion, these
findings, taken together, suggest that a moderate increase
of IL-1-dependent inflammation, as conferred by one IL-
1RN allele 2 can favor athletic performance, but not an
excessive increase as conferred by the IL-1RN 2/2
genotype.
It is known that there are different IL-1 gene cluster
genetic profiles between ethnic groups, and particularly
between black and white populations [35]. Therefore,
we considered only white Italian subjects, a homoge-
neous Caucasian ethnic group. A limitation of this
approach is that our results may not be applicable to
non-Caucasian subjects.
Conclusions
Our study supports the notion that the IL-1 family of
genes is significantly associated with physical performance.
The finding of a higher frequency of allele 2, and specifi-
cally of the 1/2 genotype VNTR IL-1RN, in athletes with
respect to non-athletes highlights that immune genetic
variants are involved in athletic predisposition. Based on
previous evidence of inflammatory effects of the VNTR
IL-1RN allele 2, the association of IL-1 related genes with
athlete status appears to associate a genetic predisposition
of a moderately enhanced inflammatory response. How-
ever, we cannot exclude much more indirect effects modu-
lated by IL-1ra. Immunity in physical exercise is likely
regulated by subtle tuning of cytokine levels; for example,
a partial reduction in IL-1ra could reinforce immune
defenses against exercise-associated micro-injuries.
It was beyond the scope of this study to investigate the
effects of IL-1 polymorphisms on exercise-induced sys-
temic and local inflammation, recovery capacity and type
of sport activity (aerobic vs. anaerobic; endurance vs.
sprint), which should be clarified in future studies. Of
major interest will be the comparison of aerobic vs. anae-
robic athletes; however, in the present study this kind of
evaluation was not possible due to small number of ath-
letes participating in purely anaerobic sports. Future stu-
dies relating IL-1RN genotypes and cytokine levels should
focus preferably on immune genetic profiles and inflam-
matory markers evaluated before and after exercise.
Although our results indicate an association between the
IL-1 family of cytokines and athlete status, it is not clear
how, specifically, the VNTR IL-1RN polymorphism affects
the phenotype promoting a relationship between this allele
and grade of athletic performance.
In this study we focused on 2 SNPs of the IL-1B gene
and 1 VNTR in the IL-1RN gene because these are the
most frequently studied polymorphisms of the IL-1b
and IL-1ra cytokines, which have been associated with a
variety of human conditions. Interestingly, athlete status
may constitute a confounding factor contributing to
variability of results concerning the association of the
IL-1RN polymorphisms with pathologic conditions [61].
Our present results should prompt larger studies on
additional polymorphisms in the IL-1 family in relation
to physical performance and elite athletic grade, particu-
larly, those located in the IL-1ra gene, as the SNP at
position +2018.
In conclusion, we demonstrated in a cross-sectional
study that a polymorphism potentially able to modulate
the levels of the IL-1ra cytokine, and indirectly IL-1 (a
and b) activity, is associated with athlete status. Further
research into immune factors that increase athletic perfor-
mance will help to inform the design of how immune
modulators may improve recovery or implement cure
interventions after injuries. Our finding suggests that clini-
cal trials performed to assess efficacy of various treatments
for athlete’s recovery should probably differentiate subjects
on a genetic basis in addition to etiology to maximize the
chances of observing statistically significant and reproduci-
ble results. Our study suggests cytokines are important
molecules to further explore in relation to sports activity.
Overall, this study may contribute to an increased under-
standing of the genetic basis of athletic performance. It
may also increase our understanding of inflammatory
mechanisms associated with intensive exercise.
Additional file 1: Table 7 Genotype frequencies of IL-1B promoter
at position -511 in female and male athletes. Table 8 Genotype
frequencies of IL-1B exon 5 at position +3954 in female and male
athletes. Table 9 Genotype frequencies of IL-1RN VNTR in female
and male athletes. Frequencies of IL-1B and IL-1RN genotype
frequencies stratified by athlete gender.
Click here for file
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